184 related articles for article (PubMed ID: 31473917)
1. The Genomic Landscape of Sporadic Prolactinomas.
De Sousa SMC; Wang PPS; Santoreneos S; Shen A; Yates CJ; Babic M; Eshraghi L; Feng J; Koszyca B; Roberts-Thomson S; Schreiber AW; Torpy DJ; Scott HS
Endocr Pathol; 2019 Dec; 30(4):318-328. PubMed ID: 31473917
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
3. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
[TBL] [Abstract][Full Text] [Related]
4. Screening of
Tuncer FN; Çiftçi Doğanşen S; Serbest E; Tanrıkulu S; Ekici Y; Bilgiç B; Yarman S
Genet Test Mol Biomarkers; 2018 Dec; 22(12):702-708. PubMed ID: 30461320
[No Abstract] [Full Text] [Related]
5. Whole-Exome Sequencing Study of Thyrotropin-Secreting Pituitary Adenomas.
Sapkota S; Horiguchi K; Tosaka M; Yamada S; Yamada M
J Clin Endocrinol Metab; 2017 Feb; 102(2):566-575. PubMed ID: 27854551
[TBL] [Abstract][Full Text] [Related]
6. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
7. ras mutations in human prolactinomas and pituitary carcinomas.
Cai WY; Alexander JM; Hedley-Whyte ET; Scheithauer BW; Jameson JL; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1994 Jan; 78(1):89-93. PubMed ID: 8288721
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
9. Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans.
Bernard V; Bouilly J; Beau I; Broutin I; Chanson P; Young J; Binart N
Neuroendocrinology; 2016; 103(6):738-45. PubMed ID: 26641246
[TBL] [Abstract][Full Text] [Related]
10. Genetic testing in prolactinomas: a cohort study.
Boukerrouni A; Cuny T; Anjou T; Raingeard I; Ferrière A; Grunenwald S; Maïza JC; Marquant E; Sahakian N; Fodil-Cherif S; Salle L; Niccoli P; Randrianaivo H; Sonnet E; Chevalier N; Thuillier P; Vezzosi D; Reynaud R; Dufour H; Brue T; Tabarin A; Delemer B; Kerlan V; Castinetti F; Barlier A; Romanet P
Eur J Endocrinol; 2023 Dec; 189(6):567-574. PubMed ID: 37956455
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing studies of nonfunctioning pituitary adenomas.
Newey PJ; Nesbit MA; Rimmer AJ; Head RA; Gorvin CM; Attar M; Gregory L; Wass JA; Buck D; Karavitaki N; Grossman AB; McVean G; Ansorge O; Thakker RV
J Clin Endocrinol Metab; 2013 Apr; 98(4):E796-800. PubMed ID: 23450047
[TBL] [Abstract][Full Text] [Related]
12. Molecular screening of pituitary adenomas for gene mutations and rearrangements.
Herman V; Drazin NZ; Gonsky R; Melmed S
J Clin Endocrinol Metab; 1993 Jul; 77(1):50-5. PubMed ID: 8100831
[TBL] [Abstract][Full Text] [Related]
13. Pituitary tumours: molecular and genetic aspects.
De Sousa SMC; Lenders NF; Lamb LS; Inder WJ; McCormack A
J Endocrinol; 2023 Jun; 257(3):. PubMed ID: 36951812
[TBL] [Abstract][Full Text] [Related]
14. Whole-exome identifies RXRG and TH germline variants in familial isolated prolactinoma.
Melo FM; Couto PP; Bale AE; Bastos-Rodrigues L; Passos FM; Lisboa RG; Ng JM; Curran T; Dias EP; Friedman E; De Marco L
Cancer Genet; 2016 Jun; 209(6):251-7. PubMed ID: 27245436
[TBL] [Abstract][Full Text] [Related]
15. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas.
Ronchi CL; Peverelli E; Herterich S; Weigand I; Mantovani G; Schwarzmayr T; Sbiera S; Allolio B; Honegger J; Appenzeller S; Lania AG; Reincke M; Calebiro D; Spada A; Buchfelder M; Flitsch J; Strom TM; Fassnacht M
Eur J Endocrinol; 2016 Mar; 174(3):363-72. PubMed ID: 26701869
[TBL] [Abstract][Full Text] [Related]
16. Clinical characterization of familial isolated pituitary adenomas.
Daly AF; Jaffrain-Rea ML; Ciccarelli A; Valdes-Socin H; Rohmer V; Tamburrano G; Borson-Chazot C; Estour B; Ciccarelli E; Brue T; Ferolla P; Emy P; Colao A; De Menis E; Lecomte P; Penfornis F; Delemer B; Bertherat J; Wémeau JL; De Herder W; Archambeaud F; Stevenaert A; Calender A; Murat A; Cavagnini F; Beckers A
J Clin Endocrinol Metab; 2006 Sep; 91(9):3316-23. PubMed ID: 16787992
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in MEN1 gene study for pituitary tumor pathogenesis.
Kameya T; Tsukada T; Yamaguchi K
Front Horm Res; 2004; 32():265-91. PubMed ID: 15281352
[TBL] [Abstract][Full Text] [Related]
18. The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas.
Fryer AA; Zhao L; Alldersea J; Boggild MD; Perrett CW; Clayton RN; Jones PW; Strange RC
Carcinogenesis; 1993 Apr; 14(4):563-6. PubMed ID: 8472315
[TBL] [Abstract][Full Text] [Related]
19. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
20. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
